Behavioral Intervention for HIV and HCV-Uninfected Injection Drug Users
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00164372 |
Recruitment Status
:
Completed
First Posted
: September 14, 2005
Last Update Posted
: September 27, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections Hepatitis C | Behavioral: Peer Education Intervention | Phase 2 Phase 3 |
CIDUS III/DUIT is a five-city (Baltimore, Chicago, Los Angeles, New York, and Seattle) randomized controlled trial to develop and evaluate the efficacy of a six-session behavioral intervention for HIV and HCV uninfected injection drug users between the ages of 15 and 30 years. The primary goals of the intervention are to:
- decrease the shared use of syringes and other injection paraphernalia,
- decrease sexual risk behaviors associated with HIV and HCV infection, and
- decrease the incidence of hepatitis C virus (HCV) infection.
The intervention arm consists of six small-group training and skills-building sessions to teach and reinforce peer education activities around decreasing sex and injection risk behaviors for HIV and HCV infection. In the fifth session, participants practice peer education around sex or injection risk behaviors within their community. The control arm consists of six video and discussion sessions to control for attention. Prior to study enrollment, all participants in both arms receive HIV and HCV testing with client-centered pre- and post-test counseling to also control for the demand for risk reduction information. Behavioral assessments (by audio computer assisted self interviewing) and blood draws (for serologic testing) occur at baseline, 3 and 6 month follow-up. 3285 participants completed the baseline visit, of whom 1564 tested HIV and HCV seronegative and returned for test results making them eligible to enroll in the intervention trial. Of the eligible participants, 854 were randomized into the trial. 606 and 591 returned for 3 and 6 month follow-up assessments, respectively, and 712 participants completed at least one follow-up visit.
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 1400 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Collaborative Injection Drug Users Study III/Drug Users Intervention Trial (CIDUS III/DUIT) |
Study Start Date : | May 2002 |
Actual Primary Completion Date : | December 2006 |
Actual Study Completion Date : | December 2006 |
- 1. decrease in the number and proportion of times participants practiced vaginal or anal sex without a condom.
- 2. decrease in the overall number of persons participants shared syringes or injection equipment with.
- 3. decrease in the number and proportion of injections done with a syringe previously used by another person.
- 4. decrease in the number and proportion of times participant used another person's equipment to prepare or divide drugs before injecting.
- 1. decrease the incidence of HCV infection.
- 2. decrease the frequency of injecting in high-risk settings.
- 3. increase the frequency of drug treatment entry or decrease the frequency of injection drug use.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years to 30 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- age 15-30 years old
- self-reported illicit drug injection within the past 6 months
- live in the geographic region under study and plan to stay for >12 months
- willing to provide a blood sample for serologic testing
- willing to provide basic contact information for follow-up
- able to communicate in English
- had not participated in the pilot study or previously enrolled in the trial
- not concurrently participating in other HIV or HCV intervention trials
- tested HIV and HCV seronegative at baseline
Exclusion Criteria:

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00164372
United States, California | |
Health Research Association | |
Los Angeles, California, United States, 90010 | |
United States, Illinois | |
University of Illinois at Chicago | |
Chicago, Illinois, United States, 60612 | |
United States, Maryland | |
Johns Hopkins University | |
Baltimore, Maryland, United States, 21205 | |
United States, New York | |
New York Academy of Medicine | |
New York, New York, United States, 10029 | |
United States, Washington | |
Public Health Seattle and King County | |
Seattle, Washington, United States, 98104 |
Principal Investigator: | Richard S. Garfein, PhD, MPH | Centers for Disease Control and Prevention |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Centers for Disease Control and Prevention |
ClinicalTrials.gov Identifier: | NCT00164372 History of Changes |
Other Study ID Numbers: |
CDC-NCHSTP-2934 U64/CCU317662, U64/CCU517656, U64/CCU917655, U64 CCU217659, U64/CCU071615 |
First Posted: | September 14, 2005 Key Record Dates |
Last Update Posted: | September 27, 2012 |
Last Verified: | September 2012 |
Keywords provided by Centers for Disease Control and Prevention:
IV Drug users HIV hepatitis C virus HIV Seronegativity |
Additional relevant MeSH terms:
Hepatitis Hepatitis C HIV Infections Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Flaviviridae Infections |
RNA Virus Infections Lentivirus Infections Retroviridae Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |